Rituxan (rituximab) / Zenyaku Holdings, Biogen, Roche  >>  Phase 2
Welcome,         Profile    Billing    Logout  

545 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Rituxan (rituximab) / Roche
2018-004618-17: Immunological treatment for Schizophrenia Immunologisk behandling av schizofreni

Not yet recruiting
2
12
Europe
MabThera, Concentrate for solution for infusion, MabThera
Region Örebro län, Region Örebro län
Treatment-resistant patients with schizophrenia spectrum disorder (SSD), Treatment-resistant patients with schizophrenia spectrum disorder (SSD), Psychiatry and Psychology [F] - Mental Disorders [F03]
 
 
2018-004619-28: Immunological treatment of Obsessive-Compulsive Disorder Immunologisk behandling av tvångssyndrom

Not yet recruiting
2
12
Europe
MabThera, Concentrate for solution for infusion, MabThera
Region Örebro län, Region Örebro län
Treatment-resistant patients with Obsessive Compulsive Disorder (OCD), Treatment-resistant patients with Obsessive Compulsive Disorder (OCD), Psychiatry and Psychology [F] - Mental Disorders [F03]
 
 
2018-003483-32: BLINAtumomab after R-CHOP debulking therapy for patients with Richter Transformation.

Not yet recruiting
2
35
Europe
blinatumomab, blinatumomab, Concentrate for solution for injection/infusion, BLINCYTO
FILO, AMGEN
Richter transformation, Richter transformation, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
NCT00577278: A Phase II Study of Allo-HCT for B-Cell NHL Using Zevalin, Fludarabine and Melphalan

Checkmark P2 data - 1st line fNHL
Jun 2012 - Jun 2012: P2 data - 1st line fNHL
Completed
2
41
US
rituximab, IDEC-C2B8, IDEC-C2B8 monoclonal antibody, Mabthera, MOAB IDEC-C2B8, Rituxan, fludarabine phosphate, 2-F-ara-AMP, Beneflur, Fludara, melphalan, Alkeran, CB-3025, L-PAM, L-phenylalanine mustard, L-Sarcolysin, sirolimus, AY 22989, Rapamune, rapamycin, SLM, tacrolimus, FK 506, Prograf, allogeneic hematopoietic stem cell transplantation, indium In 111 ibritumomab tiuxetan, IDEC-In2B8, yttrium Y 90 ibritumomab tiuxetan, 90Y ibritumomab tiuxetan, IDEC Y2B8, Y90 Zevalin, Y90-labeled ibritumomab tiuxetan, laboratory biomarker analysis
City of Hope Medical Center, National Cancer Institute (NCI)
Graft Versus Host Disease, Leukemia, Lymphoma
05/19
12/23
IELSG30, NCT00945724 / 2009-011789-26: Safety and Feasibility Study of Combination of State of Art Chemoimmunotherapy, Intensive Central Nervous System Prophylaxis and Scrotal Irradiation to Treat Primary Diffuse Large B-cell Lymphoma of Testis

Active, not recruiting
2
54
Europe
Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone, liposomal cytarabine, methotrexate
International Extranodal Lymphoma Study Group (IELSG)
Large B-cell Diffuse Lymphoma of Testis
06/19
12/23
PIVeR, NCT03458260 / 2017-000719-17: Study of Pixantrone in CD20+ Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma

Active, not recruiting
2
74
Europe
Pixantrone, Pixuvri, Ifosfamide, Holoxan, Etoposide, Vepeside, Rituximab, Mabthera, Transplant
The Lymphoma Academic Research Organisation
Aggressive Non-Hodgkin Lymphoma
06/19
03/25
2019-000256-33: A study of Rituximab treatment in patients with Psychosis an/or Obsessive Compulsive Disorder, with a suspected involvement of the immune system

Not yet recruiting
2
40
Europe
Infusion, Mabthera
Uppsala University Hospital, Research funding
Obsessive-compulsive disorder (OCD) or Obsessive-compulsive behaviour (OCB) or psychotic disorder (PD) in which there is an indication of immune system involvement., Obsessive-compulsive or psychotic disorders., Psychiatry and Psychology [F] - Behaviours [F01]
 
 
NCT02329080: New Combination of Chemoimmunotherapy for Systemic B-cell Lymphoma With Central Nervous System Involvement

Active, not recruiting
2
76
Europe, RoW
Methotrexate, Rituximab, Cytarabine, Thiotepa, liposomial cytarabine, Etoposide, Ifosfamide, Carmustine, whole brain radiotherapy
International Extranodal Lymphoma Study Group (IELSG)
Diffuse Large B-cell Lymphoma
08/19
12/23
2014-005493-11: Study the action of a single dose of intrathecally-infused rituximab upon cerebro-spinal fluid (CSF) biological targets, assuming that a definitive action upon CSF biological targets would be strongly predictive of a delayed clinical action in patients with Progressive Multiple Sclerosis. Montrer qu'un médicament (le Rituximab) injecté dans le liquide céphalo-rachidien (on parle alors d'injection intrathécale) a un effet majeur sur des marqueurs biologiques impliqués dans le processus responsable du handicap dans la forme progressive de la SEP.

Not yet recruiting
2
12
Europe
méthylprednisolone, rituximab, Powder for infusion, Solution for injection, Solution for infusion, Méthylprednisolone Mylan, Mabthera
Centre Hospitalier de Pau, Centre Hospitalier de Pau, Ministère de la Santé
Patients included in our study suffer from a progressive form of Multiple sclerosis and will be treated by intravenous and intrathecal rituximab, with intravenous methylprednisolone. Patients atteints de sclérose en plaques secondairement progressive recevant un traitement par rituximab intrathécal et intraveineux sous couvert de méthylprednisolone intraveineuse., Patients in the progressive phase of multiple sclerosis will received drugs combining venous and intrathecal infusions. Drugs were already used in both ways. Traitement de patients atteints de sclérose en plaques progressive par un médicament administré en perfusion et par ponction lombaire., Diseases [C] - Nervous System Diseases [C10]
 
 
GELTAMO-IMCL-2015, NCT02682641 / 2015-004158-17: Ibrutinib in Combination With Rituximab in Patients With Indolent Clinical Forms of MCL

Active, not recruiting
2
50
Europe
IBRUTINIB, Imbruvica, Rituximab
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea, Janssen-Cilag, S.A.
Mantle Cell Lymphoma
12/19
12/24
2018-002364-44: Clinical study of ibrutinib and rituximab in untreated marginal zone lymphomas

Ongoing
2
175
Europe
MabThera Uso sottocutaneo, MabThera, Imbruvica, [NA], Solution for injection, Concentrate for solution for infusion, Capsule, hard, MabThera, Imbruvica
IELSG - INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP, Janssen-Cilag AG, F. Hoffmann La Roche Ltd, Janssen Pharmaceutica NV
Previously untreated and symptomatic patients with histologically proven CD20-positive marginal zone B-cell lymphoma (MZL) in need of systemic treatment, Previously untreated marginal zone lymphoma, Diseases [C] - Cancer [C04]
 
 
2018-003560-31: Copanlisib and Standard Immuno-Chemotherapy (R-CHOP) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Copanlisib und Standard-Immunochemotherapie (R-CHOP) in Patienten mit diffusem großzelligem B-Zell-Lymphom (DLBCL)

Ongoing
2
80
Europe
Copanlisib, BAY84-1236, Lyophilisate for solution for infusion
Universitätsklinikum Münster, Bayer HealthCare Pharmaceuticals Inc.
diffuse large B-cell lymphoma diffuses großzelliges B-Zell-Lymphom, malignant disease of the lymphatic system bösartige Erkrankung des lymphatischen Systems, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
ACTRN12613000106730: A Phase 2 Study of patients treated for relapsed Follicular Lymphoma: with Revlimid (Registered Trademark) consolidation added to Rituximab maintenance therapy in those remaining Positron Emission Tomography (PET) positive (ALLG NHL26)

Completed
2
80
 
Australasian Leukaemia and Lymphoma Group, Australasian Leukaemia and Lymphoma Group
Relapsed Follicular Lymphoma
 
 
NCT06336395: Ma-Spore ALL 2020 Study

Recruiting
2
500
RoW
Prednisolone, Dexamethasone, Vincristine, Methotrexate, L-Asparaginase, Pegylated asparaginase, Erwinase, Dasatinib, Imatinib, Cyclophosphamide, Cytarabine, Mercaptopurine, Thioguanine, Rituximab, Doxorubicin, Fludarabine
National University Hospital, Singapore
B Lymphoblastic Leukemia
03/30
03/30
NCT01856192: Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma

Checkmark Maintenance in DLBCL: ASH 2015
Dec 2015 - Dec 2015: Maintenance in DLBCL: ASH 2015
Active, not recruiting
2
349
US
Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Asta B 518, B-518, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, WR-138719, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin HCl, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, hydroxydaunorubicin, Rubex, Laboratory Biomarker Analysis, Lenalidomide, CC-5013, CC5013, CDC 501, Revlimid, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, Perrigo Prednisone, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisone Intensol, Prednisonum, Prednitone, Promifen, Rayos, Servisone, SK-Prednisone, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, Ikgdar, Mabtas, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Riabni, Rituxan, Rituximab ABBS, Rituximab ARRX, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, Rituximab Biosimilar SIBP-02, rituximab biosimilar TQB2303, Rituximab PVVR, Rituximab-abbs, Rituximab-arrx, Rituximab-pvvr, RTXM83, Ruxience, Truxima, Vincristine Sulfate, Kyocristine, Leurocristine Sulfate, Leurocristine, sulfate, Oncovin, Vincasar, Vincosid, Vincrex, Vincristine, sulfate
National Cancer Institute (NCI)
Ann Arbor Stage II Diffuse Large B-Cell Lymphoma, Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma
03/20
12/24
2019-000842-36: Polatuzumab vedotin combined with standard chemo-immunotherapy drugs in diffuse large B-cell lymphoma

Not yet recruiting
2
56
Europe
Polatuzumab Vedotin, Lyophilisate for solution for infusion
The Clatterbridge Cancer Centre NHS Foundation Trust, Roche Products Ltd
Diffuse large B-cell lymphoma in patients with co-morbidities who cannot tolerate full dose R-CHOP., A cancer of the blood affecting B-cells., Diseases [C] - Cancer [C04]
 
 
NCT01359592: S1001 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma

Completed
2
159
US
rituximab, cyclophosphamide, doxorubicin hydrochloride, prednisone, vincristine sulfate, R-CHOP regimen, laboratory biomarker analysis, fludeoxyglucose F 18, selective external radiation therapy, yttrium Y 90 ibritumomab tiuxetan
SWOG Cancer Research Network, National Cancer Institute (NCI)
Lymphoma
06/20
12/23
2019-003632-23: Lenalidomide and Ibrutinib in association with R-MPV first-line treatment of Primary Central Nervous System Lymphoma for patients aged 18 to 60 Lénalidomide et Ibrutinib en association avec le R-MPV en traitement d’induction de première ligne pour les patients âgés de 18 à 60 ans présentant un lymphome primitif du système nerveux central (LCP).

Not yet recruiting
2
128
Europe
Ibrutinib 140 mg, Rituximab, Methotrexate, Procarbazine, Vincristine, Prednisone, Capsule, hard, Solution for infusion, Capsule, Tablet, Revlimid 5 mg, Revlimid 10 mg, Imbruvica 140 mg
Institut Curie, PHRC-K 2018 Public Health Grant, CELGENE SAS, JANSSEN-CILAG, KEOCYT SAS
Primary Central Nervous System Lymphoma (PCNSL) in patients aged 18 to 60, in first-line treatment Lymphome primitif du système nerveux central chez des patients âgés de 18 à 60 ans, en traitement de première ligne, Primary Central Nervous System Lymphoma in patients aged 18 to 60, first treatment Lymphome primitif du système nerveux central chez des patients âgés de 18 à 60 ans, 1er traitement, Diseases [C] - Cancer [C04]
 
 
ChiCTR1800016724: A single-arm, phase 2 study evaluating the efficacy and safety of combination of lenalidomide and R-ICE in patients of relapsed/refractory non-GCB subtype DLBCL previously treated with R-CHOP

Recruiting
2
28
 
combination of RICE and lenalidomide
ZhuJiang Hospital of Southern Medical University; ZhuJiang Hospital of Southern Medical University, self-prepared
diffuse large B cell lymphoma
 
 
2011-000792-14: Etude de phase II évaluant la tolérance et l’efficacité d’un traitement de consolidation par Rituximab sous-cutané à faibles doses chez des patients présentant une leucémie lymphoïde chronique en réponse après traitement d’induction.

Not yet recruiting
2
35
Europe
Solution for infusion, Mabthera
Institut Paoli-Calmettes, Programme Hospitalier de Recherche Clinique (PHRC)
Leucémie lymphoïde chronique (LLC), Diseases [C] - Blood and lymphatic diseases [C15]
 
 
2018-002641-11: Study on the efficacy of rituximab in patients with polymyalgia rheumatica Onderzoek naar de effectiviteit van rituximab bij patiënten met polymyalgia rheumatica

Not yet recruiting
2
40
Europe
rixathon, L01X C02, rixathon
Sint Maartenskliniek, Sint Maartenskliniek
polymyalgia rheumatica, polymyalgia rheumatica, Diseases [C] - Immune System Diseases [C20]
 
 
TOLERA, NCT04120831: Tolerance Enhancement in RA

Recruiting
2
20
Europe
Abatacept Injection, Rituximab
University of Erlangen-Nürnberg Medical School
Rheumatoid Arthritis
09/20
12/22
NCT01092182: Phase II Study of Dose-Adjusted EPOCH-Rituximab in Adults With Untreated Burkitt Lymphoma and c-MYC+ Diffuse Large B-Cell Lymphoma

Completed
2
194
US
EPOCH-R, Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin, Rituximab, EPOCH-RR
National Cancer Institute (NCI)
Burkitt Lymphoma, Diffuse Large B-cell Lymphoma, c-MYC Positive, Plasmablastic Lymphoma
09/20
02/23
NCT03746223: Intravitreal Methotrexate and R2(Rituximab & Lenalidomide) Regimen in Newly-diagnosed Primary Vitreoretinal Lymphoma

Recruiting
2
42
RoW
Methotrexate, Rituximab, Lenalidomide
Peking Union Medical College Hospital
Primary Intraocular Lymphoma
11/20
10/25
NCT00006436: EPOCH and Rituximab to Treat Non-Hodgkin's Lymphoma in Patients With HIV Infection

Active, not recruiting
2
68
US
Rituximab, Rituxan, Filgrastim, Neupogen, EPOCH, etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin hydrochloride
National Cancer Institute (NCI)
Lymphoma, AIDS-related, Lymphoma, Large B-Cell, Diffuse
11/20
03/27
ChiCTR2000029385: Lenalidomide with Rituximab and IMED in Relapsed and Refractory non-GCB DLBCL: a Phase II Clinical Trial

Recruiting
2
40
 
LR-IMED
Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center, no
lymphoma
 
 
2019-002373-59: A phase II trial investigating Gemcitabine/Oxaliplatin/Rituximab with Tafasitamab (MOR208) for patients aggressive Lymphoma. Eine Phase-II-Studie zur Untersuchung von Gemcitabin/Oxaliplatin/Rituximab mit Tafasitamab (MOR-00208) bei Patienten mit aggressivem Lymphom.

Ongoing
2
64
Europe
Tafasitamab, MOR00208, Lyophilisate for solution for infusion, MINJUVI® 200 mg Pulver für ein Konzentrat zur Herstellung einer Infusionslösung
University Medical Center of the Johannes Gutenberg University Mainz, Incyte Corporation
Malignant B-cell lymphoma Aggressives B-Zell Lymphom, Malignant Lymphoma Aggressives Lymphom, Diseases [C] - Cancer [C04]
 
 
NCT03304288: The Combination of Low-dose Rituximab and ATRA as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia

Active, not recruiting
2
168
RoW
Rituximab, All-trans retinoic acid
Peking University People's Hospital, Beijing Hospital, Navy General Hospital, Beijing, Beijing Tongren Hospital
Immune Thrombocytopenia
01/21
02/21
NCT00492050: Bortezomib and Rituximab for Patients With Waldenstrom's Macroglobulinemia

Active, not recruiting
2
46
US
Bortezomib, Velcade, LDP-341, MLN341, PS-341, Rituximab, Rituxan, Valacyclovir, Valtrex
M.D. Anderson Cancer Center, Millennium Pharmaceuticals, Inc.
Waldenstrom's Macroglobulinemia
02/21
06/24
NCT03949062: Study Evaluating the Safety and Efficacy of iR2 in Untreated and Unfit Elderly Patients With DLBCL

Active, not recruiting
2
30
RoW
Ibrutinib, Imbruvica, Lenalidomide, Relvimid, Rituximab, Rituxan
Ruijin Hospital
Diffuse Large B Cell Lymphoma
03/21
05/22
NCT02900976: Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive, CD20-Positive Post-Transplant Lymphoproliferative Disorder

Active, not recruiting
2
18
US
Allogeneic LMP1/LMP2-Specific Cytotoxic T-Lymphocytes, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, Ikgdar, Mabtas, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Riabni, Rituxan, Rituximab ABBS, Rituximab ARRX, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, Rituximab Biosimilar SIBP-02, rituximab biosimilar TQB2303, Rituximab PVVR, Rituximab-abbs, Rituximab-arrx, Rituximab-pvvr, RTXM83, Ruxience, Truxima
Children's Oncology Group, National Cancer Institute (NCI)
EBV-Related Post-Transplant Lymphoproliferative Disorder, Monomorphic Post-Transplant Lymphoproliferative Disorder, Polymorphic Post-Transplant Lymphoproliferative Disorder, Recurrent Monomorphic Post-Transplant Lymphoproliferative Disorder, Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder, Refractory Monomorphic Post-Transplant Lymphoproliferative Disorder, Refractory Polymorphic Post-Transplant Lymphoproliferative Disorder
03/21
09/24
2018-001850-80: Acalabrutinib and rituximab in elderly patients with untreated mantle cell lymphoma

Not yet recruiting
2
80
Europe
acalabrutinib, Mabthera, Capsule, hard, Concentrate for solution for infusion, Mabthera
Skåne University Hospital, Nordic Lymphoma Group, Astra Zeneca
Mantle Cell Lymphoma (MCL), Mantle Cell Lymphoma (MCL), Diseases [C] - Blood and lymphatic diseases [C15]
 
 
NCT02232386 / 2014-002714-23: Phase 2 Study to Assess Activity & Safety of Front-line Ibrutinib + Rituximab in Unfit Chronic Lymphocytic Leukemia

Active, not recruiting
2
156
Europe
Ibrutinib, Rituximab
Gruppo Italiano Malattie EMatologiche dell'Adulto
Chronic Lymphocyte Leukemia, Adult Patients
04/18
04/24
2019-002499-14: RELYAGE (Relapse LYmphoma AGEd) : Assessment of survival and autonomy with Rituximab-Lenalidomide and Rituximab-Chemotherapy for elderly patients with relapsed diffuse large-B cell lymphoma : a randomized phase II RELYAGE (RELAPSE LYMPHOMA AGED): ETUDE DE PHASE II RANDOMISEE EVALUANT LA SURVIE AVEC PRESERVATION DE L’AUTONOMIE DE RITUXIMAB PLUS CHIMIOTHERAPIE OU RITUXIMAB PLUS LENALIDOMIDE CHEZ DES PATIENTS AGES EN RECHUTE D’UN LYMPHOME DIFFUS A GRANDES CELLULES B

Not yet recruiting
2
114
Europe
rituximab, Capsule, hard, Powder for solution for infusion, Solution for infusion, revlimid, gemcitabine, oxaliplatine, bendamustine, Mabthera
CHU Amiens-Picardie, DGOS
diffuse large B cell lymphoma lymphome diffus à grandes cellules, lymphoma lymphome, Diseases [C] - Cancer [C04]
 
 
2020-004409-30: Treatment with venetoclax consolidated with ibrutinib and rituximab to increase the possibility of minimal residual disease in patient with chronic lymphotic leukemia Trattamento con venetoclax consolidato con ibrutinib e rituximab per aumentare possibilità di malattia minima residua in paziente con leucemia linfatica cronica

Not yet recruiting
2
55
Europe
venclyxto, [venclyxto], Modified-release tablet, Venclyxto
OSPEDALE SAN RAFFAELE, AbbVie
Previously Untreated Chronic Lymphophatic Leukaemia Leucemia Linfatica Cronica non precedentemente trattata, Previously untreated low-risk blood cancer Tumore del sangue a basso rischio, non precedentemente trattato, Diseases [C] - Cancer [C04]
 
 
2021-002348-57: A Randomized, Parallel Group, Single-Blind, Phase 2 Study to Evaluate the immune response of two classes of SARS-Cov-2 Vaccines employed as Second Boost in Patients under current Rituximab Therapy and no humoral response after standard mRNA vaccination

Ongoing
2
60
Europe
Comirnaty, BNT162B2, Injection, Comirnaty concentrate for dispersion for injection, COVID-19 Vaccine Moderna dispersion for injection, Vaxzevria
Medical University of Vienna, Medical University of Vienna
Vaccination against SARS-CoV-2 in patients with rituximab therapy, Rituximab has been shown to impair humoral responses to various vaccines including SARS-CoV-2 vaccination., Diseases [C] - Immune System Diseases [C20]
 
 
NCT04025593: Biomarker Guided Treatment in DLBCL

Recruiting
2
128
RoW
Cyclophosphamide, Rituximab, Doxorubicin, Vincristine, Prednisone, Ibrutinib, Lenalidomide, chidamide, decitabine
Ruijin Hospital
Diffuse Large B Cell Lymphoma
07/21
06/23
2021-001973-21: Extension of Study GNC-401 with temelimab in patients with Multiple Sclerosis under treatment with rituximab

Not yet recruiting
2
40
Europe
Temelimab, GNbAC1, Solution for infusion
GeNeuro Innovation SAS, GeNeuro Innovation SAS
Multiple Sclerosis, Multiple Sclerosis, Diseases [C] - Nervous System Diseases [C10]
 
 
FIL_V-RBAC, NCT03567876: Rituximab, Bendamustine and Cytarabine Followed by Venetoclax in High Risk Elderly Patients With MCL

Active, not recruiting
2
141
Europe
Venetoclax, Venclyxto (commercial name)
Fondazione Italiana Linfomi - ETS, AbbVie
Lymphoma, Mantle-Cell
07/21
07/25
NCT04062448: A Study of Ibrutinib in Combination With Rituximab, in Japanese Participants With Waldenstrom's Macroglobulinemia (WM)

Completed
2
16
Japan
Ibrutinib, PCI-32765, Rituximab
Janssen Pharmaceutical K.K.
Waldenstrom Macroglobulinemia
08/21
03/23
C-R-HDMTX, NCT04516655: A Phase II Trail of Chidamide ,Rituximab and Methotrexate in Lymphoma Patients

Not yet recruiting
2
51
NA
chidamide combined with rituximab and high-dose methotrexate
Fudan University
Central Nervous System Lymphoma
09/21
08/23
VeRitAs, NCT03455517 / 2018-000877-61: Activity and Safety of Front-line Venetoclax and Rituximab in Young and Fit Patients With Chronic Lymphocytic Leukemia

Completed
2
77
Europe
Venetoclax, Rituximab
Gruppo Italiano Malattie EMatologiche dell'Adulto
Chronic Myeloid Leukemia
09/21
05/23
2021-000679-35: SATELITE “Salvage Therapy for Patients with Inadequate Response to Standard of Care Therapy in Granulomatosis with Polyangiitis” SATELITE "Traitement de sauvetage pour les patients ayant une réponse inadéquate au traitement de référence dans la granulomatose avec polyangéite"

Not yet recruiting
2
42
Europe
Concentrate for solution for infusion, Solution for injection, Tablet, Rituximab, ROACTEMRA, ORENCIA, Methotrexate, Mycophénolate mofétil, Azathioprine
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP), ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS
Granulomatosis with Polyangiitis Granulomatose avec polyangéite, Granulomatosis with Polyangiitis Granulomatose avec polyangéite, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
2021-000468-32: Study for patients with mantle cell lymphoma (one type of lymphomas = lymph node cancer), aimed to answer the question if patients who relapse after previous therapy with Bruton tyrosine kinase inhibitor (type of biologivcal treatment) will be beneficiary adding of polatuzumab vedotin (new type of biological treatment) to commonly used treatment with bendamustine and rituxima (combination of chemotherpay and biological treatment) Studie pro pacienty s lymfomem z plášťových buněk (jeden z podtypů lymfomu), která se snaží odpovědět na otázku, zda u pacientů, u kterých selhala předchozí léčba inhibitory Brutonovy kinázy (typ biologické léčby), bude přinosem přidání polatuzumab vedotinu (nový typ biologické léčby) k již běžně používané záchranné léčbě (kombinace bendamustinu a rituximabu (tj. chemoterapie a biologické léčby)

Not yet recruiting
2
21
RoW
Polatuzumab vedotin, Bendamustine Accord 25 mg/ml, Mabthera, RO5541077, Powder for concentrate for solution for infusion, Concentrate for solution for infusion, Polivy, Bendamustine Accord, Mabthera
Kooperativní lymfomová skupina, z.s., Kooperativní lymfomová skupina, z.s.
Mantle cell lymphoma lymfom z plášťových buněk, aggressive lymph node cancer of B-cell origin agresivní nádorové onemocnění z mízních uzlin z B-buněk, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
PembroWM, NCT03630042 / 2018-001767-23: Investigating the Safety and Efficacy of Rituximab and Pembrolizumab in Relapsed/Refractory Waldenström's Macroglobulinaemia

Completed
2
17
Europe
Pembrolizumab, Rituximab
University College, London, Merck Sharp & Dohme LLC
Waldenstrom Macroglobulinemia
09/21
06/23
ChiCTR-IIR-16009117: The efficacy and safety evaluation of immunochemotherapy with R-MAD in newly-diagnosed primary central nervous system lymphoma

Not yet recruiting
2
100
 
rituximab ;none
Beijing Tiantan Hospital, Capital Medical University; Beijing Tiantan Hospital, Capital Medical University, National Natural Science Foundation of China
primary central nervous system lymphoma
 
 
NCT03931642: BLINAtumomab After R-CHOP Debulking Therapy for Patients With Richter Transformation

Completed
2
41
Europe
RCHOP, Blinatumomab
French Innovative Leukemia Organisation, Amgen
Richter Syndrome
10/21
10/22
2020-004977-38: Study to determine the efficacy of Tafasitamab and lenalidomide administered in association with rituximab in frontline Diffuse Large B-Cell Lymphoma Patients of 80 y/o or older .

Not yet recruiting
2
71
Europe
Tafasitamab, MOR208, Powder and solvent for solution for injection, Capsule, hard, Zelvina
LYSARC, Incyte
Frontline DLBCL, Diffuse Large B Cells Lymphoma, Diseases [C] - Cancer [C04]
 
 
2020-002622-87: A phase II trial of belimumab in combination withrituximab/venetoclax in patients with refractory orrelapsed chronic lymphocytic leukemia

Not yet recruiting
2
120
Europe
Benlysta 200 mg Injektionslösung im Fertigpen, n.a., Injection, Benlysta 200 mg Injektionslösung im Fertigpen Benlysta 200 mg Injektionslösung in einer Fertigspritze
University Hospital Tuebingen, GlaxoSmithKline
Refractory or relapsed chronic lymphocytic leukemia, Refractory or relapsed chronic lymphocytic leukemia, Diseases [C] - Cancer [C04]
 
 
2019-004613-14: Clinical trial conducted to evaluate the effectiveness of a combination of drugs called venetoclax and rituximab adapted to the state of minimal residual disease in patients with untreated chronic lymphocytic leukemia Badanie kliniczne prowadzone celem oceny skuteczności terapii kombinacją leków o nazwie wenetoklaks i rytuksymab dostosowanej do stanu minimalnej choroby resztkowej u pacjentów z do tej pory nieleczoną przewlekłą białaczką limfocytową

Not yet recruiting
2
103
Europe
Venetoclax, Rituximab, Film-coated tablet, Concentrate for solution for infusion, Venclyxto, MabThera
POLISH ADULT LEUKEMIA GROUP, AbbVie, Inc.
Chronic lymphocytic leukemia Przewlekła białaczka limfocytowa, Chronic lymphocytic leukemia is a type of tumor that affects lymphocytes and lymph nodes. In CLL, lymphocytes are produced faster and live longer, which is why their number in the blood is too large. Przewlekła białaczka limfocytowa jest rodzajem nowotworu oddziałującym na limfocyty i węzły chłonne. W PBL limfocyty są wytwarzane szybciej i żyją dłużej, dlatego ich liczba we krwi jest zbyt duża., Diseases [C] - Cancer [C04]
 
 
NCT04588194: Romiplostim, Rituximab and Dexamethasone as Frontline Treatment for Immune Thrombocytopenia

Recruiting
2
12
RoW
Romiplostim, Rituximab, Dexamethasone
David Gomez Almaguer
Immune Thrombocytopenia, Thrombotic Thrombocytopenic Purpura
11/21
11/22
EPIC, NCT03719989 / 2012-001194-81: Azacitidine and Rituximab-GDP Immunochemotherapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Not yet recruiting
2
27
RoW
azacitidine plus R-GDP, N/E
Seoul National University Hospital
Diffuse Large B Cell Lymphoma, Relapsed Non Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma
11/21
11/23
LYTPET, NCT00324467: Tailoring Treatment for B Cell Non-hodgkin's Lymphoma Based on PET Scan Results Mid Treatment

Active, not recruiting
2
150
Canada
Cyclophosphamide, Cytoxan®, Neosar®, Doxorubicin, Adriamycin ®, Rubex®, Vincristine, Oncovin ®, Vincasar Pfs ®, Vincristine Sulfate, LCR, VCR, Prednisone, Sterapred®, Sterapred® DS, Prednisone Intensol, Ondansetron, Zofran®, Zofran® ODT, Zuplenz®, Dexamethasone, Decadron®, Dexamethasone Intensol®, Dexpak® Taperpak®, Diphenhydramine, Aler-Dryl®, Benadryl®, Nytol®, Diphenhist®, Acetaminophen, Tylenol®, Ifosfamide, Ifex®, Isophosphamide, Mesna (IV), Mesnex®, Sodium 2-mercaptoethanesulfonate, Mesna (oral), Carboplatin, CBDCA, Etoposide, Etopophos®, VP-16, Rituximab, Rituxan®, PET Scan, Positron emission tomography (PET) scan
British Columbia Cancer Agency, Hoffmann-La Roche
Lymphoma, Non-Hodgkin, Advanced Stage Diffuse Large B-Cell Non-Hodgkin's Lymphoma
12/21
12/21
2021-004864-81: Proposta di studio per valutare l’efficacia di Obinutuzumab, un anticorpo anti-CD20, in pazienti con nefropatia membranosa intolleranti, resistenti o dipendenti alla terapia con Rituximab (studio ORION) OBINUTUZUMAB FOR PRIMARY MEMBRANOUS NEPHROPATHY: A PILOT STUDY IN PATIENTS WITH RITUXIMAB-RESISTANT OR RITUXIMAB-DEPENDENT NEPHROTIC SYNDROME AND IN PATIENTS INTOLERANT TO RITUXIMAB (THE ORION STUDY)

Not yet recruiting
2
20
Europe
GAZYVARO, OMNIPAQUE, [L01XC15], [Ioexolo], Concentrate and solvent for solution for infusion, Solution for injection, GAZYVARO - 1000 MG - CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO - 1000MG/40ML - 1 FLACONCINO, OMNIPAQUE - 300 MG I/ML SOLUZIONE INIETTABILE FLACONE IN POLIPROPILENE DA 50 ML
IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI, Roche, IRCCS Istituto Mario Negri
PRIMARY MEMBRANOUS NEPHROPATHY Nefropatia membranosa primaria, PRIMARY MEMBRANOUS NEPHROPATHY Nefropatia membranosa primaria, Diseases [C] - Male diseases of the urinary and reproductive systems [C12]
 
 
NCT06454266: First-line Treatment of PCNSL With the Combination of Orelabrutinib, Rituximab, and Methotrexate (ORM Regimen)

Recruiting
2
21
RoW
ORM regimen, Orelabrutinib, Rituximab and Methotrexate
Ningbo No. 1 Hospital
Primary Central Nervous System Lymphoma
06/24
06/27
ChiCTR2100050169: Chidamide combined with rituximab in the treatment of recurrent / refractory elderly (over 65 years old) diffuse large B-cell lymphoma: a phase II clinical study

Recruiting
2
30
 
Chidamide combined with rituximab
Tianjin Union Medical Center; Tianjin Union Medical Center, self-financing
lymphoma
 
 
ChiCTR1900027811: Ibubutinib, Rituximab and Methotrexate in Newly-dignosed Primary Central Nervous System Lymphoma (PCNSL)

Not yet recruiting
2
31
 
Ibrutinib + Rituximab + Methotrexate
Xuan Wu Hospital, Capital Medical University; Xuan Wu Hospital, Capital Medical University, Self-raising
primary central nervous system lymphoma
 
 
2019-004822-15: A Clinical Trial Examining the Effects of Temelimab Following Rituximab Treatment in Patients with Multiple Sclerosis

Not yet recruiting
2
40
Europe
Temelimab, GNbAC1, Solution for infusion
GeNeuro Innovation SAS, GeNeuro Innovation SAS
Multiple Sclerosis, Multiple Sclerosis, Diseases [C] - Nervous System Diseases [C10]
 
 
NCT04460248: Zanubrutinib, Lenalidomide and Rituximab (ZR2) in Elderly Treatment-naive Patients With Diffuse Large B-cell Lymphoma (DLBCL)

Active, not recruiting
2
40
RoW
Zanubrutinib, Lenalidomide and Rituximab (ZR2)
Ruijin Hospital
Diffuse Large B Cell Lymphoma
02/22
08/23
CTR20150541: A Phase II clinical study of AT-101 in the treatment of patients with chronic lymphocytic leukemia

Terminated
2
92
China
R-(-)-gossypol (AT 101) - Ascentage Pharma, Rituxan (rituximab) - Biogen, Zenyaku Holdings, Roche
Jiangsu Yasheng Pharmaceutical Development Co., Ltd.
Relapsed or refractory chronic lymphocytic leukemia (CLL)
 
 
AITL, NCT04319601: Rituximab Combined With Chidamide and Lenalidomide for r/r

Recruiting
2
26
RoW
Rituximab, chidamide, lenalidomde
Zhejiang Cancer Hospital
Angioimmunoblastic T-cell Lymphoma, Chemotherapy Effect, Chemotherapeutic Toxicity
03/22
12/22
NCT04994626: Ibrutinib Combined With Rituximab for Treatment of Relapsed Refractory MYD88 and CD79A/B (or CD79B Alone) DLBCL Who Have Received at Least Two Prior Therapies

Not yet recruiting
2
20
NA
Ibrutinib Combined With Rituximab, Imbruvica Combined With Rituximab
Chinese Academy of Medical Sciences
DLBCL, MYD88 Gene Mutation, CD79A Gene Mutation, CD79B Gene Mutation, Relapse, Refractory Lymphoma
04/22
07/25
ACTRN12619000990123: A study to look at the safety and efficacy of Acalabrutinib and Rituximab followed by chemo with or without Autologous stem cell transplant (ASCT) and maintenance Acalabrutinib and Rituximab in fit patients with previously untreated mantle cell lymphoma.

Active, not recruiting
2
44
 
Australasian Leukaemia and Lymphoma Group, Acerta
Mantle cell Lymphoma
 
 
2021-006030-40: EFFICACY OF POLATUZUMAB, BENDAMUSTINE AND RITUXIMAB IN PATIENTS WITH RELAPSED/ REFRACTORY MANTLE CELL LYMPHOMA

Not yet recruiting
2
16
Europe
Powder for solution for infusion, Powder for concentrate for solution for infusion, Concentrate for solution for infusion, Polivy, Bendamustin Accord, MabThera
Med. Univ. Wien, Klinik f. Innere Med I, Onkologie
MANTLE CELL LYMPHOMA, MANTLE CELL LYMPHOMA, Diseases [C] - Cancer [C04]
 
 
NCT02398240: Brentuximab for Newly Diagnosed Hodgkin Disease

Completed
2
40
US
Brentuximab Vedotin, Adcetris, Doxorubicin, Doxil, Adriamycin, Vincristine, Oncovin, Rituximab, Rituxan
Mitchell Cairo
Hodgkin Lymphoma
06/22
12/22
RIPPLE, NCT04246359: Rituximab and Pegylated Interferon α-2b in Patients With Indolent B-cell Lymphoma

Recruiting
2
52
RoW
Rituximab Biosimilar, HLX01, Pegylated Interferon α-2b
Huiqiang Huang
Lymphoma, B-Cell
06/22
01/23
2021-005861-41: A research study to evaluate the safety and effectiveness and dosing of Zilovertamab Vedotin with R-CHP in adults with DLBCL Un estudio en investigación para evaluar la seguridad y eficacia y la dosificación de Zilovertamab Vedotin con R-CHP en adultos con LDCBG.

Ongoing
2
60
Europe
zilovertamab vedotin, Endoxan, Doxorubicin-Ebewe, Prednisone, Truxima, MK-2140, Lyophilisate for solution for infusion, Powder for solution for injection, Concentrate for solution for infusion, Tablet, Endoxan, Doxorubicin-Ebewe, Prednison 50 mg GALEN, Truxima
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
Diffuse Large B-cell Lymphoma (DLBCL) Linfoma difuso de linfocitos B grandes (LDCBG), Phase II dose confirmation study in diffuse large B-cell lymphoma Estudio fase II de confirmación de dosis en Linfoma difuso de linfocitos B grandes., Diseases [C] - Cancer [C04]
 
 
NCT04337827: Rituximab and Acalabrutinib in Newly Diagnosed B Cell Post Transplant Lymphoproliferative Disorder

Terminated
2
6
US
Rituximab, Rituxan, Mabthera, Acalabrutinib, ACP-196, CT scans
Deepa Jagadeesh
Post-transplant Lymphoproliferative Disorder
06/22
12/22
NCT05050630: Phase II Trial of Tirelizumab Combined With R2-ICE Regimen in the Treatment of rrDLBCL/HGBL

Recruiting
2
73
RoW
TR2-ICE
Affiliated Hospital to Academy of Military Medical Sciences, Beijing Cancer Hospital, Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Age Range ≥16 Years, Gender Unlimited, Histopathology Confirmed Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma, Received Prior First-line Chemotherapy for DLBCL or HGBL, Failed to Reach CR for Four Cycles, or Relapsed, At Least One Positive Lesion According to the 2014 Lugano Criteria for Hodgkin's and Non-Hodgkin's Lymphoma, ECOG Physical Status Score is 0-3, The Researchers Judged That Life Expectancy Was at Least Three Months, Understand and Voluntarily Sign Written Informed Consent
07/22
07/23
PUMCH-NHL-007, NCT04899453: Intravitreal MTX and ZR Regimen in Newly Diagnosed PVRL

Recruiting
2
42
RoW
Methotrexate, Rituximab, Zanubrutinib
Peking Union Medical College Hospital
Primary Vitreoretinal Lymphoma
08/22
08/24
ChiCTR2000035106: A multicenter, double-arm, randomized, prospective II phase controlled clinical trial to evaluate the efficacy and safety of dexitabine combined with R-GDP compared with R-CHOP in patients with mid-term PET-CT positive newly diagnosed diffuse large B-cell lymphoma ((DLBCL)).

Recruiting
2
116
 
RCHOP ;D-R-GDP
Union Medical College Affiliated Hospital of Tongji Medical College, Huazhong University of Science and Technology; Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, self-financing
Diffuse large B-cell lymphoma
 
 
RRAIHA01, NCT04083014: Single-dose Anti-CD20 Antibody With Bortezomib for Relapsed Refractory Autoimmune Hemolytic Anemia

Completed
2
33
RoW
combination of a single dose anti-CD20 antibody and bortezomib, Rituximab Injection, Bortezomib for Injection
Peking Union Medical College Hospital
Autoimmune Hemolytic Anemia, Autoimmune Hemolytic Anemia and Autoimmune Thrombocytopenia
03/24
03/24
NCT05014100: Orelabrutinib in Combination With R2 Regimen for R/R CD20+ B-cell Lymphoma

Not yet recruiting
2
55
NA
Orelabrutinib tablet, Lenalidomide, RR
Puyang Oilfield General Hospital
B-cell Lymphoma
09/22
09/23
NCT04544059: Lenalidomide Plus R-CHOP for CNS Relapse Prophylaxis in Diffuse Large B-cell Lymphoma

Not yet recruiting
2
87
RoW
Lenalidomide
Nanfang Hospital of Southern Medical University
Diffuse Large B Cell Lymphoma
10/22
10/24
NCT06201507: BV-AVD-R Treatment Children Hodgkin's Lymphoma

Enrolling by invitation
2
44
RoW
Brentuximab vedotin, Adcetris, Rituximab, Rituxan, Doxorubicin, Doxil, Adriamycin, Vincristine, Oncovin, Dacarbazine, DTIC
Beijing Children's Hospital
Hodgkin Lymphoma
12/24
12/25
POLARIS, NCT05076097: A Study of OLR in First-line Treatment of Mantle Cell Lymphoma

Recruiting
2
29
RoW
Orelabrutinib in in combination of rituximab and lenalidomide(OLR), OLR Arm
Tianjin Medical University Cancer Institute and Hospital
Mantle Cell Lymphoma
10/22
10/23
PrE0405, NCT03834688: Phase II Study of Bendamustine and Rituximab Plus Venetoclax in Untreated Mantle Cell Lymphoma Over 60 Years of Age

Active, not recruiting
2
33
US
Venetoclax, GDC-0199, ABT-199, RO5537382, Bendamustine, Bendamustine hydrochloride, Rituximab, Chimeric anti-CD20 monoclonal antibody, Rituxan
PrECOG, LLC., Genentech, Inc.
Mantle Cell Lymphoma
10/22
11/24
NCT02636322: Smart Start: A Phase II Study of Rituximab, Lenalidomide, and Ibrutinib

Completed
2
60
US
Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, hydroxydaunorubicin, Rubex, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16-213, VP-16, VP-16-213, Ibrutinib, BTK Inhibitor PCI-32765, CRA-032765, Imbruvica, PCI-32765, Lenalidomide, CC-5013, CC5013, CDC 501, Revlimid, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisonum, Prednitone, Promifen, Servisone, SK-Prednisone, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Rituxan, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, RTXM83, Vincristine Sulfate, Kyocristine, Leurocristine sulfate, Leurocristine, sulfate, Oncovin, Vincasar, Vincosid, Vincrex, Vincristine, sulfate
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Diffuse Large B-Cell Lymphoma Unclassifiable
10/22
10/22
NCT04938297: Rituximab,Zanubrutinib in Combination With Lenalidomide, Followed by Zanubrutinib or Lenalidomide Maintenance in Patients With Primary or Secondary CNS Lymphoma

Recruiting
2
100
RoW
Rituximab, Lenalidomide, Zanubrutinib, Lenalidomide, Zanubrutinib, Lenalidomide
Henan Cancer Hospital
Central Nervous System Lymphoma
10/22
12/25
NCT03620903 / 2017-004362-95: Efficacy of First Line B-RI for Treatment Naive Waldenström's Macroglobulinemia

Active, not recruiting
2
53
Europe
Ibrutinib / Bortezomib / Rituximab, Imbruvica / Velcade / Mabthera
Christian Buske, University of Ulm, ClinAssess GmbH, Zentrum für Klinische Studien Ulm, Hoffmann-La Roche, Johnson & Johnson
Waldenstrom Macroglobulinemia
11/22
09/29
NCT04022005: Chidamide + R-GemOx Regimen as Salvage Treatment for Transplant-ineligible Patients With Relapsed/Refractory DLBCL

Completed
2
54
RoW
Chidamide, Rituximab, Gemcitabine,Oxaliplatin
Sun Yat-sen University
Lymphoma, Large B-Cell, Diffuse
11/22
03/23
ChiCTR2100044313: A single-arm, prospective, multi-center phase II clinical study of tislelizumab injection combined with R-CHOP in the treatment of primary mediastinal large B-cell lymphoma

Recruiting
2
20
China
tislelizumab injection combined with R-CHOP
Affiliated Tumor Hospital of Xinjiang Medical University ; Affiliated Tumor Hospital of Xinjiang Medical University, BeiGene (Shanghai) bio-pharmaceutical Co. , Ltd.
Primary mediastinal Large B-Cell Lymphoma.
 
 
PCR, NCT05115409: Anti-PD-1 Antibody Plus Chidamide and Rituximab Regimen in Relapsed or Refractory DLBCL

Not yet recruiting
2
27
NA
Anti-PD-1 Antibody Plus Chidamide and Rituximab
Sun Yat-sen University, Chipscreen Biosciences, Ltd.
Relapsed or Refractory DLBCL
12/22
12/24
NCT04659434: Sintilimab Plus R-GemOx as Second-line Salvage Therapy in Patients With R/R DLBCL

Not yet recruiting
2
51
RoW
Sintilimab, IBI308
Qian Wenbin
Diffuse Large B Cell Lymphoma, Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
12/22
12/25
NCT01059786: Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia

Checkmark P2 data in HCL
Nov 2011 - Nov 2011: P2 data in HCL
Active, not recruiting
2
69
US
Pentostatin, Nipent, Rituximab, Rituxan, Bendamustine, Bendeka, Treanda, Acetaminophen, Tylenol, Diphenhydramine, Benadryl, Epinephrine, Adrenaline, Antihistamines, Corticosteroids, Corticoid, Bronchodilators, Broncholytic, Intravenous (IV) Saline
National Cancer Institute (NCI)
Hairy Cell Leukemia
12/22
12/25
NCT04235036: Ibrutinib and Rituxan for Chronic GVHD

Terminated
2
19
US
Rituximab, Ibrutinib
Northside Hospital, Inc., Pharmacyclics LLC.
Graft Vs Host Disease
12/22
12/22
NCT04425824: Toripalimab Combine With Rituximab for Treatment of Relapsed Refractory CD20 Positive Diffuse Large B-cell Lymphoma

Not yet recruiting
2
20
RoW
Toripalimab combine with Rituximab, JS001 combine with rituxan
Chinese Academy of Medical Sciences
Diffuse Large B-cell Lymphoma, Rituximab, Toripalimab
12/22
12/22
R2DLBCL80, NCT04622579: Lenalidomide Combined With Rituximab as Front-line Therapy for DLBCL Patients Aged Over 80 Years

Recruiting
2
20
RoW
lenalidomide combined with rituximab
Guangdong Provincial People's Hospital, Guangzhou First People's Hospital, Foshan First People's Hospital, Huizhou Municipal Central Hospital, Shantou Central Hospital
Diffuse Large B Cell Lymphoma, Age Over 80 Years
12/22
03/23
2021-001864-12: VEMURAFENIB + RITUXIMAB (VR) AS A CHEMOTHERAPY-FREE ALTERNATIVE TO CLADRIBINE + RITUXIMAB (CDAR) IN FRONT-LINE HAIRY CELL LEUKEMIA (HCL): A PHASE-2 RANDOMIZED MULTICENTER TRIAL VEMURAFENIB + RITUXIMAB (VR) COME ALTERNATIVA NON CHEMIOTERAPICA A CLADRIBINA + RITUXIMAB (CDAR) NEL TRATTAMENTO DI PRIMA LINEA DELLA TRICOLEUCEMIA: UNO STUDIO MULTICENTRICO RANDOMIZZATO DI FASE-2

Not yet recruiting
2
120
Europe
Rituximab, cladribina, Vemurafenib, [L01X- C02], [NA], L01XE15, Concentrate for solution for infusion, Solution for injection, Tablet, MABTHERA - 1 FIALA 500 MG 50 ML, LITAK - 2MG/ML SOLUZIONE INIETTABILE - USO SOTTOCUTANEO - FLAC. (VETRO) 5 ML 5 FLACONCINI, MABTHERA - 2 FIALE 100 MG 10 ML, ZELBORAF - 240 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (ALU/ALU) 56 COMPRESSE
DIPARTIMENTO DI MEDICINA, UNIVERSITà DI PERUGIA, Fondi del Dipartimento di Medicina e Chirurgia
Previously untreated patients with diagnosis of HCL Pazienti precedentemente non trattati con diagnosi di HC, Previously untreated patients with diagnosis of HCL Pazienti precedentemente non trattati con diagnosi di HC, Diseases [C] - Cancer [C04]
 
 
RTXFIRPedINS, NCT04783675: Efficacy and Safety of Rituximab in the First Episode of Pediatric Idiopathic Nephrotic Syndrome

Completed
2
44
RoW
Rituximab
Children's Hospital of Fudan University, Children's Hospital of Nanjing Medical University, Wuhan Union Hospital, China, Anhui Provincial Children's Hospital, Children's Hospital Affiliated to Zhengzhou University/Henan Children's Hospital, The first affiliated hospital of Zhongshan university, Shandong Provincial Hospital, Xuzhou Children's Hospital
Steroid-Sensitive Nephrotic Syndrome
01/23
01/23
2019-001734-34: Efficacy and safety of LNP023 compared with rituximab in subjects with idiopathic membranous nephropathy.

Not yet recruiting
2
72
Europe
Rituximab, LNP023, Capsule, hard, Concentrate for solution for infusion, MabThera 500 mg concentrate for solution for infusion, MabThera 100 mg concentrate for solution for infusion
Novartis Pharma AG, Novartis Farmacéutica, S.A., Novartis Pharma AG
Idiopathic Membranous nephropathy, Kidney disease, Diseases [C] - Immune System Diseases [C20]
 
 
2020-002935-30: Venetoclax in combination with Ibrutinib and Rituximab or conventional chemotherapy (Bendamustine) and Ibrutinib and Rituximab in patients with Mantle Cell Lymphoma. Venetoclax in Kombination mit Ibrutinib und Rituximab oder konventionelle Chemotherapie (Bendamustin) und Ibrutinib und Rituximab bei Patienten mit Mantelzell-Lymphoms.

Not yet recruiting
2
150
Europe
Film-coated tablet, IMBRUVICA®140 mg Filmtabletten, Venclyxto® 10 mg Filmtabletten, Venclyxto® 50 mg Filmtabletten, Venclyxto® 100 mg Filmtabletten
University Medical Center of the Johannes Gutenberg-University Mainz, AbbVie Inc., Janssen Pharmaceutica NV
Mantle Cell Lymphoma Mantelzell-Lymphom, malignant lymph node disease bösartige Lymphknotenerkrankung, Diseases [C] - Cancer [C04]
 
 
ZUMA-14, NCT04002401: Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Rituximab in Participants With Refractory Large B-Cell Lymphoma

Hourglass Mar 2021 - Dec 2021 : Initial data from ZUMA-14 trial for refractory DLBCL
Checkmark From ZUMA-14 trial in combination with either rituximab or lenalidomide for DLBCL at ASH 2019
Nov 2019 - Nov 2019: From ZUMA-14 trial in combination with either rituximab or lenalidomide for DLBCL at ASH 2019
Completed
2
27
US
Axicabtagene Ciloleucel, Yescarta®, Rituximab, RITUXAN®, Fludarabine, Cyclophosphamide
Kite, A Gilead Company
Refractory Large B-cell Lymphoma
01/23
01/23
BRIDGE, NCT04736914: Zanubrutinib-based Induction and Maintenance Therapy in Young and Fit Patients With Untreated Mantle Cell Lymphoma

Recruiting
2
47
RoW
R-CHOP/R-DHAOx； Zanubrutib（induction）； ASCT conditioning ； Zanubrutinib（Maintenance）, R-CHOP，R-DHAOx，Brukinsa
Sun Yat-sen University
Mantle Cell Lymphoma
01/23
02/26
NCT00596154: Rituximab, Methotrexate, Procarbazine and Vincristine Followed by High-dose Chemotherapy With Autologous Stem-cell Rescue in Newly-diagnosed Primary CNS Lymphoma

Checkmark P2 data - ASCO
Jun 2012 - Jun 2012: P2 data - ASCO
Completed
2
33
US
Rituximab, Methotrexate, Vincristine, Procarbazine, PBPCs collection, Busulfan, Thiotepa, and Cyclophosphamide, During each cycle, you will receive Rituximab typically as an outpatient on day 1 and then be, admitted on day 2 to receive the other chemotherapy. You will be in the hospital for about 5 days and will be re-admitted to the hospital about 9 days, later to start the next cycle. After each cycle of chemotherapy you will take a medicine called G-CSF to protect you against, infection. PBPCs will be collected when determined by your doctor and may occur with cycle 1 or cycle 2., You will be admitted again for the high-dose chemotherapy and will receive supportive, medications to help avoid complications, including antibiotics and blood transfusions. Three, drugs, Busulfan, Thiotepa, and Cyclophosphamide will be given to you over 8 days. After a, rest period of approximately 1-2 days, we will give your PBPCs (or bone marrow) back to you, by vein. You will be in the hospital for at least 3 weeks.
Memorial Sloan Kettering Cancer Center
CNS Lymphoma, CNS Brain Cancer, Non-Hodgkin's Lymphoma
02/23
02/23
NCT04224571: CCCG Relapsed Acute Lymphoblastic Leukemia 2017 Study in Children

Completed
2
208
RoW
Bortezomib Injection, Velcade, rituximab injection, Mab Thera
Chinese University of Hong Kong, Shanghai Children's Medical Center
Acute Lymphoblastic Leukemia, in Relapse
02/23
02/23
NCI-2014-01707, NCT02199184: Dose Adjusted EPOCH Regimen in Combination With Ofatumumab or Rituximab in Treating Patients With Newly Diagnosed or Relapsed or Refractory Burkitt Lymphoma or Relapsed or Refractory Acute Lymphoblastic Leukemia

Completed
2
14
US
Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin HCl, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, hydroxydaunorubicin, Rubex, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16, VP 16-213, VP-16, VP-16-213, VP16, Ofatumumab, Arzerra, GSK1841157, HuMax-CD20, HuMax-CD20, 2F2, Kesimpta, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, Perrigo Prednisone, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisone Intensol, Prednisonum, Prednitone, Promifen, Rayos, Servisone, SK-Prednisone, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Riabni, Rituxan, Rituximab ABBS, Rituximab ARRX, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, Rituximab Biosimilar SIBP-02, rituximab biosimilar TQB2303, Rituximab PVVR, rituximab-abbs, Rituximab-arrx, Rituximab-pvvr, RTXM83, Ruxience, Truxima, Vincristine Sulfate, Kyocristine, Leurocristine Sulfate, Leurocristine, sulfate, Oncovin, Vincasar, Vincosid, Vincrex, Vincristine, sulfate
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
AIDS-Related Burkitt Lymphoma, Atypical Burkitt/Burkitt-Like Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Recurrent Acute Lymphoblastic Leukemia, Recurrent Burkitt Lymphoma, Refractory Acute Lymphoblastic Leukemia, Refractory Burkitt Lymphoma
02/23
02/23
MPAL, NCT02135874: Clofarabine, Idarubicin, Cytarabine, Vincristine Sulfate, and Dexamethasone in Treating Patients With Newly Diagnosed or Relapsed Mixed Phenotype Acute Leukemia

Completed
2
16
US
Clofarabine, Clofarex, Clolar, Cytarabine, .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-Beta-D-arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Cytosine-beta-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453, Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycadron, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decadron DP, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasone Intensol, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Fluorodelta, Fortecortin, Gammacorten, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, TaperDex, Visumetazone, ZoDex, Idarubicin, 4-Demethoxydaunomycin, 4-demethoxydaunorubicin, 4-DMDR, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Rituxan, Rituximab ABBS, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, rituximab biosimilar TQB2303, rituximab-abbs, RTXM83, Truxima, Sorafenib, BA4 43 9006, BAY 43-9006, Bay-439006, Sorafenib Tosylate, BAY 43-9006 Tosylate, BAY 54-9085, Nexavar, sorafenib, Vincristine, LEUROCRISTINE, VCR, Vincrystine, Vincristine Sulfate, Kyocristine, Leurocristine sulfate, Leurocristine, sulfate, Oncovin, Vincasar, Vincosid, Vincrex, Vincristine, sulfate
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Acute Bilineal Leukemia, Acute Biphenotypic Leukemia, Acute Leukemia of Ambiguous Lineage, Acute Undifferentiated Leukemia, Mixed Phenotype Acute Leukemia, Mixed Phenotype Acute Leukemia, B/Myeloid, Not Otherwise Specified, Mixed Phenotype Acute Leukemia, T/Myeloid, Not Otherwise Specified, Recurrent Mixed Phenotype Acute Leukemia
02/23
02/23
NCT06254560: Rituximab for Serious Aplastic Anemia With Platelet Transfusion Refractoriness

Recruiting
2
20
RoW
Rituximab, Mabthera
Institute of Hematology & Blood Diseases Hospital, China
Severe Aplastic Anemia, Platelet Transfusion Refractoriness
12/26
12/27
CORAL, NCT05209308: Rituximab Plus Venetoclax in Combination With Zandelisib in Subjects With CLL

Withdrawn
2
42
US
Zandelisib, ME-401, Rituximab, Rituxan, MabThera, Venetoclax, Venclexta
MEI Pharma, Inc., Kyowa Kirin, Inc.
CLL
03/23
03/23
 

Download Options